MAI Capital Management’s Definium Therapeutics DFTX Stock Holding History

MAI Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$267K	Buy	5,686 +5,583	+5,420%	+$138K	﹤0.01%	1654
2026 Q1	$1.95K	Buy	103 +44	+75%	+$747	﹤0.01%	3939
2025 Q4	$791	Buy	59 +49	+490%	+$606	﹤0.01%	3701
2025 Q3	$118	Hold	10	–	–	﹤0.01%	3734
2025 Q2	$65	Hold	10	–	–	﹤0.01%	3907
2025 Q1	$59	Hold	10	–	–	﹤0.01%	3381
2024 Q4	$70	Buy	+10	New	+$69	﹤0.01%	3443
2022 Q2	–	Sell	-880	Closed	-$15K	–	944
2022 Q1	$15K	Hold	880	–	–	﹤0.01%	897
2021 Q4	$18K	Buy	+880	New	+$28.1K	﹤0.01%	903

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

MAI Capital Management's DFTX Position: Q2 2026 in Review

MAI Capital Management increased its Definium Therapeutics (DFTX) stake by 5,420% in Q2 2026, buying an estimated $138K and bringing the position to 5,686 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #1654.

MAI Capital Management first reported a position in DFTX in Q4 2021 and has held it in 9 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

MAI Capital Management held 5,686 shares of Definium Therapeutics worth $267K as of Q2 2026.
MAI Capital Management bought 5,583 Definium Therapeutics shares in Q2 2026, an estimated $138K.
Definium Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1654 holding.
MAI Capital Management first reported a position in Definium Therapeutics in Q4 2021 and has held it in 9 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.